drugset / Trial / NCT00314873
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Timeline
- Start
- 2006-04
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 600 mg | Oral |